Tinzaparin sodium
As of the edition of 20 October 2026, Tinzaparin sodium is an oligosaccharide: marketed, first approved in 1991 (FR); acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Oligosaccharide
- Brand name
- Innohep
- First approved
- 18 October 1991 (FR)
- Approvals on record
- 13 in 3 regions
- Holder of the most recent approval
- LEO Pharma; 3 holders in all
- Registered trials
- 13, 2 stopped early
- Disease areas
- Heart and blood vessels; Cancer; Lungs and airways; Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 1 |
| Phase 3 | 4 | 2 | 0 | 1 |
| Phase 4 | 4 | 3 | 1 | 0 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| LEO Pharma | Applicant, Acquired holder and Lead sponsor of trials | 1995 to now |